Evidence map›Paper›PMID 26067823›Full record

ArticleLeukemia2016

IL1RAP expression as a measure of leukemic stem cell burden at diagnosis of chronic myeloid leukemia predicts therapy outcome.

N Landberg, N Hansen, M Askmyr, H Ågerstam, C Lassen, M Rissler, H Hjorth-Hansen, S Mustjoki, M Järås, J Richter and 1 more

Abstract readLetter
PubMed Publisher
In one paragraph

Article in Leukemia, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.

0numbers the graph read from it
0cells of the map it votes in
28citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

28 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Review
  6. IL-1RAP, a Key Therapeutic Target in Cancer.International journal of molecular sciences · 2022
    Review
  7. Article
  8. Review
  9. Review
  10. Review
  11. Review
  12. Article
  13. Review
  14. Article
  15. Article
  16. Article
  17. Review
  18. Review
  19. IL1RAP potentiates multiple oncogenic signaling pathways in AML.The Journal of experimental medicine · 2018
    Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

N LandbergDepartment of Clinical Genetics, Lund University, Lund, Sweden.
N HansenDepartment of Clinical Genetics, Lund University, Lund, Sweden.
M AskmyrDepartment of Clinical Genetics, Lund University, Lund, Sweden.
H ÅgerstamDepartment of Clinical Genetics, Lund University, Lund, Sweden.
C LassenDepartment of Clinical Genetics, Lund University, Lund, Sweden.
M RisslerDepartment of Clinical Genetics, Lund University, Lund, Sweden.
H Hjorth-HansenDepartment of Hematology, St Olavs Hospital, Trondheim, Norway.
S MustjokiHematology Research Unit Helsinki, Department of Clinical Chemistry and Hematology, University of Helsinki and Comprehensive Cancer Center, Helsinki University Hospital, Helsinki, Finland.
M JäråsDepartment of Clinical Genetics, Lund University, Lund, Sweden.
J RichterDepartment of Hematology and Vascular Disorders, Skåne University Hospital, Lund, Sweden.
T FioretosDepartment of Clinical Genetics, Lund University, Lund, Sweden.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

ADP-ribosyl Cyclase 1Antigens, CD34Fusion Proteins, bcr-ablHumansInterleukin-1 Receptor Accessory ProteinLeukemia, Myelogenous, Chronic, BCR-ABL PositiveNeoplastic Stem CellsProtein-Tyrosine KinasesTreatment OutcomeADP-ribosyl Cyclase 1Antigens, CD34BCR-ABL1 fusion protein, humanFusion Proteins, bcr-ablIL1RAP protein, humanInterleukin-1 Receptor Accessory ProteinProtein-Tyrosine Kinases

Identifiers

PMID26067823

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.